News

June 11, 2019

Family Friendly Research Poster Session Presenters Announced

Family Friendly Research Poster Session Presenters Announced

The Family Friendly Research Poster Session will be held on Saturday, June 29th from 6:30pm to 8:00pm at the 2019 Annual SMA Conference. 

The Family Friendly Research Poster Session allows for one-on-one interactions between families and researchers. Cure SMA has invited...

READ MORE   |  

Topics: Conference, Research, Front Page News

June 6, 2019

Biogen Issues Q2 Community Statement on Spinraza

Biogen Issues Q2 Community Statement on Spinraza

Dear members of the SMA community,

We are grateful for the opportunity to continue to help support individuals with spinal muscular atrophy (SMA), their caregivers and families. We deeply appreciate our shared goals and are dedicated to helping people with SMA, of all ages, and welcome...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

June 5, 2019

Team Cure SMA Celebrates Global Running Day!

Team Cure SMA Celebrates Global Running Day!

Happy Global Running Day! Is Global Running Day a made-up holiday? Kind of. But unlike other made-up holidays dedicated to eating pancakes or taking selfies, Global Running Day has the purpose of celebrating running and encouraging people to get active. Today, we’d love for you to...

READ MORE   |  

Topics: Events & Fundraising, Front Page News

June 4, 2019

Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers

Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers

Scholar Rock today announced positive final top-line results from the Phase 1 clinical trial of its product candidate, SRK-015, a highly specific...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

June 3, 2019

Cure SMA to Host "Evening in the Park" at Disneyland Thanks to Support from AveXis

Cure SMA to Host

Conference attendees will enjoy a magical “Evening in the Park” at Disneyland thanks to special support from AveXis, a Novartis company.

All registered attendees for the family conference will receive (1) ticket that provides twilight entry to one of the...

READ MORE   |  

Topics: Conference, Front Page News

May 28, 2019

Cure SMA to Host Adult Lounge and Expanded Adult Social at Annual Conference Thanks to Biogen and the Dhont Family Foundation

Cure SMA to Host Adult Lounge and Expanded Adult Social at Annual Conference Thanks to Biogen and the Dhont Family Foundation

Cure SMA will be offering two great programming opportunities for adults (18 and over) with SMA attending the 2019 Annual SMA Conference next month – an adult lounge and two adult social events.

Thanks to a generous grant funded by Biogen, Cure SMA will be providing an exclusive...

READ MORE   |  

Topics: Conference, Front Page News

May 24, 2019

AveXis and Cure SMA to Co-Host Webinar on the FDA's Approval of Zolgensma

On Wednesday, June 12th, at 10am CDT (8am PDT/9am MDT/11am EDT) AveXis, a Novartis company, and Cure SMA will co-host a webinar on the FDA approval of Zolgensma. This webinar will include information about the approval, dosing sites, future IT clinical trials, and more. The webinar will also include...

READ MORE   |  

Topics: Research, Front Page News

May 24, 2019

AveXis Issues Community Statement on Zolgensma Approval

AveXis Issues Community Statement on Zolgensma Approval

Dear SMA Community,

We have exciting news to share with you — a major milestone has been reached in the fight against spinal muscular atrophy (SMA)! The US Food and Drug Administration (FDA) has approved ZOLGENSMA® (onasemnogene abeparvovec-xioi) for the treatment of children...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

May 24, 2019

AveXis Receives FDA Approval of Zolgensma, a Gene Therapy, for Spinal Muscular Atrophy for Patients Under Two Years of Age

AveXis Receives FDA Approval of Zolgensma, a Gene Therapy, for Spinal Muscular Atrophy for Patients Under Two Years of Age

AveXis, Inc., a Novartis company, today announced that they have received FDA approval for Zolgensma (formerly AVXS-101), a gene therapy that replaces the survival motor neuron 1 (SMN1) gene,...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

May 21, 2019

Cure SMA Awards $150,000 Grant to Krysta Engel, PhD, University of Colorado

Cure SMA Awards $150,000 Grant to Krysta Engel, PhD, University of Colorado

Audrey Lewis founded Families of SMA, now Cure SMA, 34 years ago. Audrey recognized early on the importance of attracting new and talented researchers to SMA, with the hope that they would commit their careers to developing a treatment and cure for SMA.

Cure SMA honors Audrey’s...

READ MORE   |  

Topics: Our Impact, Research, Front Page News

Items 11 - 20 of 652  Previous12345678910Next

© 2019 Cure SMA | Cure SMA is recognized as tax-exempt under section 501(c)(3) of the Internal Revenue Code. EIN: 36-3320440. | Privacy Policy

Powered by Blackbaud
nonprofit software